First-known puberty blocker patient says 'insulting' youth gender movement makes mockery of true dysphoria
The first known patient to take puberty blockers to treat gender dysphoria sharply rebuked the modern youth gender identity movement as "insulting" in a podcast interview with the New York Times published last week.
The Times spoke with "FG," a patient in adolescent transgender medicine from the Netherlands, who was the first known person given puberty blockers at 13years-old in the 1980s to stop female development.
"FG" explained dealing with anger issues as a child and feeling uncomfortable living as a girl. The fear of going through puberty led the teen to express suicidal thoughts in a letter and eventually seek out medical treatment to stop normal development, as well as cross-sex hormones and gender reassignment surgery later on.
Now, living as a man decades later with no regrets, "FG" believes puberty blockers "saved my life."
Despite being a proponent of these medical interventions, "FG" was not supportive of the modern gender diversity movement.
"So many of the young people now want to visibly challenge the binary," New York Times reporter Azeen Ghorayshi told "FG," asking, "What do you make of that? And what do you make of what that means for getting the medical treatment that you pioneered?"
"I find that it's gone — it's gone a bit extreme to the other side," "FG" replied. "So it makes a laughingstock of what it's really about. Or at least, it seems to be a fashion statement nowadays."
"FG" equated the current gender climate to other youth rebellion movements of the past where young people forged their identities "to stand out," saying gender seemed to be another forum for that today.
"And for the group that is pure, like proper transsexuals, this flirting with pronouns and gender identity — it's insulting," "FG" continued.
"FG", who works in the medical field and asked to stay anonymous out of a desperate desire to fit in as a man, said it seemed like young people now treat their gender identity as a fad.
"Because like I said, we spend all our time trying to just fit in or be able to live the life that we feel we should have had. And it's not a great help when you've got people shouting from the barricades and trying to give you a different position, a third sex or whatever, and then talk about things that we don't want you to talk about, so that they can identify you," "FG" added.
"I don't take a lot of these people that seriously, because it does seem to be a bit of a fashion statement."
Shortly after taking office for his second term, President Donald Trump signed an executive order cutting off federal funding for institutions who engage in "chemical and surgical" sex-change procedures for minors.
"Across the country today, medical professionals are maiming and sterilizing a growing number of impressionable children under the radical and false claim that adults can change a child's sex through a series of irreversible medical interventions," the order, titled "Protecting Children from Chemical and Surgical Mutilation," states. "This dangerous trend will be a stain on our Nation's history, and it must end."
A number of hospitals nationwide challenged the order earlier this year, with some vowing to continue providing these medical interventions for minors.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
24 minutes ago
- Medscape
Fast Five Quiz: Late-Onset Pompe Disease
Multiple genetic variants have been associated with LOPD. However, the c.-32-13T>G splice site variant is found in up to 90% of adults and 50% of pediatric patients. Patients with LOPD often have compound heterozygous genotypes, with one allele carrying the common c.-32-13T>G splice-site variant and the other harboring a more deleterious GAA mutation (eg, nonsense, frameshift, or large deletion). Other variants— such as and c.1935C>A — are more commonly seen in infantile forms of Pompe disease. Learn more about the pathophysiology of LOPD. Diagnosis of LOPD typically follows a two-step approach: first, measuring GAA enzyme activity (often via dried blood spot assay) followed by confirmatory molecular genetic testing to identify pathogenic GAA variants. Although once considered a first-line diagnostic tool for LOPD, muscle biopsy is no longer preferred due to its invasive nature and the non-specificity of histologic findings. Muscle biopsy may still be considered in rare, ambiguous cases when enzyme and genetic testing are inconclusive or conflicting. CK levels might be elevated in some patients but are nonspecific and primarily serve to raise clinical suspicion. Learn more about the workup for LOPD. Enzyme replacement therapy (ERT) has significantly changed the natural history of the disease by improving survival and stabilizing motor and respiratory function. However, key limitations in skeletal muscle uptake and variability in clinical response remain. This is due to low expression of the mannose-6-phosphate receptor in muscle tissue, which hampers enzyme internalization. As a result, patients might experience a limited or plateaued response. Newer approaches, including modified ERT and gene therapy, are being developed to address this issue. High toxicity to cardiac muscle, uniform patient response, and development of cardiac hypertrophy have not been reported as key limitations. Learn more about treatment options for LOPD. NBS programs have reshaped the understanding of Pompe disease, particularly LOPD. A significant proportion of screen-positive newborns harbor genetic variants associated with LOPD, including pseudo deficiency alleles and variants of uncertain significance. These individuals are often asymptomatic at birth and might not develop symptoms for years, if at all. This has raised important clinical questions around monitoring, counseling, and when (or whether) to initiate therapy; expanded screening has also revealed that the true prevalence of LOPD might be higher than historical estimates suggested. Learn more about the management of LOPD. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication. Lead image: UCSF/Science Source
Washington Post
8 hours ago
- Washington Post
Dutch Princess Amalia undergoes surgery after breaking arm in horse riding fall
THE HAGUE, Netherlands — The heir to the Dutch throne, Princess Amalia, was recovering in a hospital Wednesday after undergoing surgery to one of her arms that she broke a day earlier when she fell off her horse, the Royal House announced. The 21-year-old, formally known as the Princess of Orange, sustained the injury on Tuesday and underwent surgery the same evening at the University Medical Center Utrecht hospital, according to a Royal House statement.
Medscape
9 hours ago
- Medscape
Global Variation in Norepinephrine Use for Paediatric Shock
Many paediatric ICU (PICU) prescribers lacked knowledge about norepinephrine (NE) formulations they prescribed, creating risks in paediatric hypotensive shock. METHODOLOGY: Researchers conducted a cross-sectional electronic survey from November 2023 to February 2024 via global paediatric critical care networks to characterise NE prescribing patterns in paediatric hypotensive shock, identify variations in dose reporting units, and assess knowledge gaps. The analysis included 424 complete responses (78.4% completion rate) from healthcare professionals, predominantly attending paediatric intensivists (81.4%). The 28-item survey gathered data on respondent demographics and NE prescribing, compounding, and administration practices. Respondents were classified into four geographical groups (Europe, America, Asia and Middle East, and Oceania) for comparison. Regional comparisons focused on differences in dosing units (NE base vs conjugated salt), initial doses, and thresholds prompting escalation to second-line therapies in hypotensive septic shock. The primary endpoint was the assessment of variability in NE dose reporting units; secondary endpoints were knowledge gaps and discrepancies in medication safety, compounding, and administration practices. TAKEAWAY: Nearly half (43.9%) of PICU prescribers were unaware of the NE formulation, and 36.1% were uncertain whether dosing units referred to NE base or conjugated salt. American and Asian/Middle Eastern respondents initiated NE infusions at half the median dose used by European prescribers (0.05 vs 0.1 mcg/kg/min; P < .001). < .001). For hypotensive septic shock, American and Asian/Middle Eastern respondents tended to add second-line vasopressors at significantly lower NE doses than Europeans (median, 0.15 and 0.2 vs 0.5 mcg/kg/min; P < .0001). < .0001). In 29.7% of PICUs, NE dose reporting lacked consensus on base vs conjugated salt, highlighting a critical standardisation gap. IN PRACTICE: "Clinicians should use norepinephrine base as their standard unit for norepinephrine dose reporting," the authors wrote. SOURCE: This study was led by Isabelle Goyer, Department of Pharmacy, CHU de Caen, Caen, France. It was published online on June 05, 2025, in the European Journal of Pediatrics . LIMITATIONS: The self-reported nature of the survey could have introduced bias and a potential for selection bias towards clinicians with a greater interest in the topic. Low response rates in certain regions, particularly non–French-speaking European and low-income countries, limited generalisability. Additionally, most respondents were physicians, with limited representation from pharmacists and nurses. DISCLOSURES: Two authors reported receiving funding from Braun Medical. The authors declared having no competing interests.
